Section 3: Production and Compounding

3PC-032

LOW-DOSE MORPHINE SOLUTION FOR SPINAL ANAESTHESIA - READY TO USE TO IMPROVE PATIENT SAFETY IN DRUG THERAPY

3PC-031

THE TRANSITION FROM THE USE OF BUPIVACAINE TO ROPIVACAINE IN THE DELIVERY ROOM, IN ORDER TO ACHIEVE A BETTER ANALGESIC EFFECT

3PC-030

PHYSICAL, CHEMICAL AND MICROBIOLOGICAL STABILITY OF SIROLIMUS 0.4% IN TOPICAL FORMULATIONS

3PC-029

QUALITY OF GEMCITABINE READY TO ADMINISTER PREPARATIONS

3PC-028

DOSE-BANDING GEMCITABINE AND STANDARDISATION OF CHEMOTHERAPY PROTOCOLS PRODUCTION

3PC-027

PRODUCTIVITY ANALYSIS OF AN AUTOMATED COMPOUNDING SYSTEM FOR INTRAVENOUS CHEMOTHERAPY

3PC-026

WHAT IS THE BEST CHEMICAL DECONTAMINATION SOLUTION FOR CONVENTIONAL ANTI-NEOPLASTIC DRUGS IN A HOSPITAL COMPOUNDING UNIT?

3PC-025

OPTIMISATION OF COMPOUNDING ORGANISATION AFTER IMPLEMENTING A ROBOTIC SYSTEM FOR AUTOMATED PREPARATION OF ONCOLOGIC DRUGS

3PC-024

THE VALIDATION OF CONTROL METHOD : THE GRAVIMETRIC ANALYSIS IN CYTOTOXIC DRUG PREPARATION

3PC-023

A RISK ANALYSIS METHOD TO EVALUATE THE IMPACT OF A CHEMOTHERAPY COMPOUNDING WORKFLOW MANAGEMENT SYSTEM ON CANCER PATIENTS' SAFETY

3PC-022

PRELIMINARY MICROBIOLOGICAL STUDY OF INJECTABLE CHEMOTHERAPY DOSE-BANDING

3PC-021

IMPACT OF A CENTRALISED INTRAVENOUS ADDITIVE SERVICE IN PATIENTS AND HEALTHCARE WORKERS RISK REDUCTION

3PC-020

NIVOLUMAB WEIGHT-BASED DOSING VS FLAT DOSE ECONOMIC ANALYSIS

3PC-019

RISK MANAGEMENT OF CROSS-CONTAMINATION OF PAEDIATRIC ANTI-CANCER PREPARATIONS USING FAILURE MODE AND EFFECTS CRITICALITY ANALYSIS

3PC-018

IMPLEMENTATION OF QUALITY CONTROL OF PAEDIATRIC CYTOTOXIC DRUG PREPARATIONS: PILOT TRIAL WITH ETOPOSIDE.

Pages